Should I buy or sell Outlook Therapeutics stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Outlook Therapeutics in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" OTLK shares. View OTLK analyst ratings or view top-rated stocks .

What is Outlook Therapeutics' stock price target for 2024?

8 brokerages have issued twelve-month target prices for Outlook Therapeutics' stock. Their OTLK share price targets range from $20.00 to $100.00. On average, they anticipate the company's stock price to reach $46.43 in the next year. This suggests a possible upside of 439.2% from the stock's current price. View analysts price targets for OTLK or view top-rated stocks among Wall Street analysts .

How have OTLK shares performed in 2024?

Outlook Therapeutics' stock was trading at $7.88 at the beginning of 2024. Since then, OTLK stock has increased by 9.3% and is now trading at $8.61. View the best growth stocks for 2024 here .

Are investors shorting Outlook Therapeutics?

Outlook Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 1,330,000 shares, an increase of 69.4% from the March 15th total of 785,300 shares. Based on an average daily trading volume, of 598,100 shares, the days-to-cover ratio is presently 2.2 days. Approximately 6.2% of the shares of the stock are sold short. View Outlook Therapeutics' Short Interest .

When is Outlook Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our OTLK earnings forecast .

How were Outlook Therapeutics' earnings last quarter?

Outlook Therapeutics, Inc. (NASDAQ:OTLK) posted its quarterly earnings data on Wednesday, February, 14th. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.20.

When did Outlook Therapeutics' stock split?

Outlook Therapeutics shares reverse split on the morning of Thursday, March 14th 2024. The 1-20 reverse split was announced on Thursday, March 14th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Outlook Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Outlook Therapeutics investors own include Matinas BioPharma (MTNB) , KushCo (KSHB) , Bionano Genomics (BNGO) , SCYNEXIS (SCYX) , Gran Tierra Energy (GTE) , ADMA Biologics (ADMA) , Zosano Pharma (ZSAN) , Novan (NOVN) , Organigram (OGI) and CNBX Pharmaceuticals (CNBX) .

How do I buy shares of Outlook Therapeutics?

Shares of OTLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:OTLK

Outlook Therapeutics (OTLK) Stock Price, News & Analysis

→ This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad)

Free OTLK Stock Alerts

$8.61

-0.14 (-1.60%)

(As of 04/17/2024 ET)

Compare

Today's Range: $8.53
▼
$9.26
50-Day Range: $5.73
▼
$11.94
52-Week Range: $4.00
▼
$40.60

Volume: 418,088 shs
Average Volume: 555,025 shs
Market Capitalization: $112.02 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $46.43

Get Outlook Therapeutics alerts:

Outlook Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.88 Rating Score
Upside/Downside: 439.2% Upside
$46.43 Price Target
Short Interest: Bearish
6.16% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.28
Based on 9 Articles This Week
Insider Trading: Acquiring Shares
$22,245 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($2.99) to ($1.84) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.00 out of 5 stars

Medical Sector

352nd out of 914 stocks

Biotechnology Industry

14th out of 47 stocks

4.4

Analyst's Opinion

Consensus Rating
Outlook Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Outlook Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
6.16% of the float of Outlook Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Outlook Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Outlook Therapeutics has recently increased by 69.36%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Outlook Therapeutics does not currently pay a dividend.
Dividend Growth
Outlook Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OTLK.

2.9

News and Social Media Coverage

News Sentiment
Outlook Therapeutics has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Outlook Therapeutics this week, compared to 3 articles on an average week.
Search Interest
81 people have searched for OTLK on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.
MarketBeat Follows
20 people have added Outlook Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 82% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Outlook Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $22,245.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 5.30% of the stock of Outlook Therapeutics is held by insiders.
Percentage Held by Institutions
Only 11.20% of the stock of Outlook Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Outlook Therapeutics are expected to grow in the coming year, from ($2.99) to ($1.84) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Outlook Therapeutics is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Outlook Therapeutics is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Wall Street Star

This Apple-like Innovator is Revolutionizing Healthcare

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

Click here to learn more about the booming eHealth industry

About Outlook Therapeutics Stock (NASDAQ:OTLK)

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

OTLK Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OTLK Stock News Headlines

March 30, 2024 | insidertrades.com

Yezan Munther Haddadin Purchases 1,882 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) Stock

April 15, 2024 | globenewswire.com

Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million

April 17, 2024 | Priority Gold (Ad)

Biden to Launch “FedNOW” [Move Your Money Now]

Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...

April 15, 2024 | investorplace.com

Biotech on a Budget: 7 Stocks Under $10 With Huge Potential

April 15, 2024 | americanbankingnews.com

Outlook Therapeutics (NASDAQ:OTLK) versus Vigil Neuroscience (NASDAQ:VIGL) Head-To-Head Contrast

April 14, 2024 | msn.com

Microsoft Outlook 2010's Default Profile Pic Was Based on Bill Gates' 1977 Mug Shot?

April 14, 2024 | msn.com

US Consumer Sentiment Falls Slightly as Outlook for Inflation Worsens

April 13, 2024 | americanbankingnews.com

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Recommendation of "Moderate Buy" from Analysts

April 17, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 11, 2024 | fxstreet.com

Fed's Williams: Outlook is uncertain, Fed must be data-dependent

April 11, 2024 | msn.com

Stock Market Today: Wall Street Falls After Hot Inflation Data Burns Hopes for a June Rate Cut

April 11, 2024 | msn.com

Bitdefender now has identity protection for Gmail and Outlook

April 10, 2024 | finance.yahoo.com

Insiders are Piling into These 10 Healthcare Stocks in 2024

April 3, 2024 | forbes.com

Users Complain Gmail Blocks Email From Microsoft Outlook—Here’s The Fix

April 3, 2024 | msn.com

Outlook.com trips over Google's spam blocking rules

March 29, 2024 | uk.investing.com

BTIG upgrades Outlook Therapeutics stock to buy, cites ONS-5010 success

March 27, 2024 | markets.businessinsider.com

Buy Rating for Outlook Therapeutics: Promising FDA Developments and Strong Financial Position Support $50 Price Target

March 27, 2024 | msn.com

Outlook Therapeutics shares rise after 'buy' rating from BTIG

March 25, 2024 | markets.businessinsider.com

Outlook Therapeutics: Buy Rating Affirmed Amid Positive European Developments and Anticipated U.S. Market Success

March 25, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Outlook Therapeutics: European Endorsement and Pivotal US Study Progress Signal Strong Market Potential

March 24, 2024 | nasdaq.com

Outlook Therapeutics Surges On Positive CHMP Opinion For ONS-5010

March 22, 2024 | msn.com

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Higher On Friday?

March 22, 2024 | marketwatch.com

Outlook Therapeutics Shares Rise Premarket on CHMP Backing of Wet AMD Drug

March 22, 2024 | msn.com

Canopy Growth, Capricor Therapeutics, GT Biopharma among healthcare movers

March 22, 2024 | markets.businessinsider.com

Outlook Therapeutics Receives Positive CHMP Opinion For ONS-5010 To Treat Wet AMD

March 22, 2024 | globenewswire.com

Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

March 19, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Outlook Therapeutics Amidst Strong Financial Positioning and Advancing Clinical Trials

See More Headlines

Receive OTLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Outlook Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/14/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 9/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:OTLK
CUSIP: N/A
CIK: 1649989
Web: www.outlooktherapeutics.com
Phone: (609) 619-3990
Fax: N/A
Employees: 24
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $46.43
High Stock Price Target: $100.00
Low Stock Price Target: $20.00
Potential Upside/Downside: +430.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.88
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.00)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-58,980,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -3,741.39%
Return on Assets: -132.37%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.44
Quick Ratio: 0.44

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.11) per share
Price / Book: -7.88

Miscellaneous

Outstanding Shares: 13,010,000
Free Float: 12,323,000
Market Cap: $113.84 million
Optionable: Not Optionable
Beta: 0.04

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Ralph H. Thurman (Age 75)
Independent Executive Chairman
Comp: $207.5k
Mr. C. Russell Trenary III (Age 66)
President, CEO & Director
Comp: $610.9k
Mr. Lawrence A. Kenyon CPA (Age 58)
Executive VP, CFO, Treasurer, Company Secretary & Director
Mr. Jeffrey Evanson (Age 55)
Chief Commercial Officer
Comp: $451.17k
Ms. Alicia Tozier
Senior Vice President, Marketing & Market Access
Mr. Joel Prieve
Senior Vice President of Licensing and M&A
Dr. Surendra Sharma M.D.
Senior Vice President of Medical Affairs
Dr. Jennifer M. Kissner Ph.D.
Senior Vice President of Clinical Development & Regulatory Affairs
Mr. Jedd Comiskey
Senior VP - Head of Europe

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OTLK Stock Analysis - Frequently Asked Questions

Should I buy or sell Outlook Therapeutics stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Outlook Therapeutics in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" OTLK shares.
View OTLK analyst ratings or view top-rated stocks.
What is Outlook Therapeutics' stock price target for 2024?: 8 brokerages have issued twelve-month target prices for Outlook Therapeutics' stock. Their OTLK share price targets range from $20.00 to $100.00. On average, they anticipate the company's stock price to reach $46.43 in the next year. This suggests a possible upside of 439.2% from the stock's current price.
View analysts price targets for OTLK or view top-rated stocks among Wall Street analysts.
How have OTLK shares performed in 2024?: Outlook Therapeutics' stock was trading at $7.88 at the beginning of 2024. Since then, OTLK stock has increased by 9.3% and is now trading at $8.61.
View the best growth stocks for 2024 here.
Are investors shorting Outlook Therapeutics?: Outlook Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 1,330,000 shares, an increase of 69.4% from the March 15th total of 785,300 shares. Based on an average daily trading volume, of 598,100 shares, the days-to-cover ratio is presently 2.2 days. Approximately 6.2% of the shares of the stock are sold short.
View Outlook Therapeutics' Short Interest.
When is Outlook Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our OTLK earnings forecast.

How were Outlook Therapeutics' earnings last quarter?: Outlook Therapeutics, Inc. (NASDAQ:OTLK) posted its quarterly earnings data on Wednesday, February, 14th. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.20.
When did Outlook Therapeutics' stock split?: Outlook Therapeutics shares reverse split on the morning of Thursday, March 14th 2024. The 1-20 reverse split was announced on Thursday, March 14th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of Outlook Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Outlook Therapeutics investors own include Matinas BioPharma (MTNB), KushCo (KSHB), Bionano Genomics (BNGO), SCYNEXIS (SCYX), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Novan (NOVN), Organigram (OGI) and CNBX Pharmaceuticals (CNBX).
How do I buy shares of Outlook Therapeutics?: Shares of OTLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OTLK) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial